Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
Merck
Moodys
McKinsey

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,182,958

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,182,958 protect, and when does it expire?

Patent 7,182,958 protects CIALIS and is included in one NDA.

Protection for CIALIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 7,182,958
Title:.beta.-carboline pharmaceutical compositions
Abstract:Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use in treating sexual dysfunction, are disclosed.
Inventor(s): Oren; Peter L. (Fishers, IN), Anderson; Neil R. (West Lafayette, IN), Kral; Martha A. (Indianapolis, IN)
Assignee: Lilly Icos LLC. (Wilmington, DE)
Application Number:10/031,464
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,182,958
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Recent additions to Drugs Protected by US Patent 7,182,958

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 7,182,958

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lilly CIALIS tadalafil TABLET;ORAL 021368-004 Jan 7, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 AB1 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,182,958

PCT Information
PCT FiledApril 26, 2000PCT Application Number:PCT/US00/11130
PCT Publication Date:February 08, 2001PCT Publication Number: WO01/08686

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.